Clinical trials: Streptococcus Pneumoniae Infection
Pneumococcal Infections
Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)
The purpose of this study is to 1) evaluate the safety and tolerability of V114 and 2) to compare the immune responses of the 15 serotypes contained in V114 with V114 versus Prevnar 13™.
- Trial name
- PNEU-AGE (NCT03950622)
- Testing
- V114, Prevnar 13®
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 1,205 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infectious Disease
PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months.
- Trial name
- NCT07333352
- Testing
- 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)
- Where
- 7 sites in China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Infections, Streptococcal
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria
The purpose of this trial is to assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A when administered either as a booster dose or as a two dose catch-up vaccination…
- Trial name
- NCT01153893
- Testing
- Pneumococcal vaccine GSK1024850A, InfanrixTM
- Where
- Nigeria
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
Prevenar 13 is safe for administration to Filipinos.
- Trial name
- NCT01396434
- Testing
- Prevenar 13
- Where
- 119 sites in Philippines
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infection
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine ([Prevnar 20™ / APEXXNAR™]) in…
- Trial name
- NCT05425732
- Testing
- V116, PCV20
- Where
- 112 sites in United States, Australia and 9 more
- Volunteers
- 2,663 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japan, Korea, and Taiwan
- Trial name
- NCT04875533
- Testing
- 20vPnC, Saline, 13vPnC
- Where
- 28 sites in Japan, South Korea and 1 more
- Volunteers
- 1,425 people, healthy volunteers welcome
- Sponsor
- Pfizer
Measles, Mumps
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00109343
- Testing
- Comparator: ProQuad™ (V221), Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
- Volunteers
- 1,027 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not previously been immunized with Pneumococcal…
- Trial name
- NCT00452452
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 9 sites in Poland
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections, HIV Infections
Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
HIV-infected people and pregnant women are at risk of developing severe pneumococcal disease. The purpose of this study is to compare the safety and immune response to two pneumococcal vaccines in HIV-infected pregnant women.
- Trial name
- NCT01443117
- Testing
- PPV-23 Vaccine, PCV-13 Vaccine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
This study is designed to find out whether HIV-positive patients whose immune systems have improved after receiving anti-HIV treatment should take azithromycin to prevent Mycobacterium avium complex (MAC) disease.
- Trial name
- NCT00000947
- Testing
- Azithromycin
- Where
- 19 sites in United States
- Volunteers
- 850 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Meningitis
Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection
Lung immune responses are regulated independently of systemic responses. Injected vaccines may induce optimal responses in blood but not at mucosal surfaces.
- Conditions
- Pneumonia, Meningitis, Invasive Pneumococcal Disease, HIV
- Trial name
- NCT00371878
- Testing
- 7-valent pneumococcal conjugate vaccine (Prevnar)
- Where
- Malawi
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Liverpool University Hospital
Pneumococcal Infection
Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers
Immune response analysis after the combination of PCV13 and PPV23 will lead to evaluate if a prime with PCV13 help to obtain a good response to repeated dose of PPV23.The hyporesponsiveness following the unconjugated vaccine is…
- Trial name
- HYPOPNEUMO (NCT02279589)
- Testing
- Pneumo 23® 0,5, Pneumo 23® 0,1, Prevenar13® 0,5
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumococcal Infections
Phase I Clinical Trial of a Candidate PCV13 in Healthy People
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.
- Trial name
- NCT05602480
- Testing
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Pneumococcal Vaccine
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
- Trial name
- NCT06337643
- Testing
- MVX01
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Matrivax Research and Development Corporation
Acute Febrile Illness, Pneumococcal Infections
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality.
- Trial name
- PREV-HOSPIT (NCT06822907)
- Testing
- Early intervention, Delayed intervention
- Where
- 24 sites in France
- Volunteers
- 1,052 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pneumococcal Infection
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
phase-1 study pneumococcal conjugate vaccine study in healthy adults
- Trial name
- NCT03549208
- Testing
- LBVE01, LBVE02, Prevnar13
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Chem
Streptococcus Pneumoniae Infection
Effect of Two Versus Three Pneumococcal Conjugate Vaccinations
Two( 2) or three (3) instead of four vaccinations before the age of 6 months with pneumococcal conjugate vaccine are presumed to protect children against invasive pneumococcal disease like meningitis, at least on the short term…
- Trial name
- MNOES (NCT00189020)
- Testing
- PCV7
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
HIV Infections, Streptococcus Pneumoniae
Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to…
- Trial name
- NCT00622843
- Testing
- pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
- Where
- 6 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Pneumococcal Infections
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
To test the hypothesis that immune responses to 23-valent pneumococcal polysaccharide vaccine (PPV-23) could be improved in Alaska Native elders by immune priming with 7-valent pneumococcal conjugate vaccine (PCV-7), we assessed…
- Trial name
- NCT00153543
- Testing
- PCV7 + PPV23, 2 months, PCV7 + PPV23, 6 months
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Pneumococcal Infections
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00452790
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 12 sites in India
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer